Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Regulus Therapeutics, a developer of medicines targeting microRNAs, has identified a third microRNA target under its pact with GlaxoSmithKline (GSK) which was signed in 2008.
Subscribe to our email newsletter
With this discovery, GSK has paid preclinical milestone to Regulus.
The agreement between the companies aims to discover and develop compounds targeting four different microRNAs in inflammation and HCV infection.
Under the deal, GSK is responsible to pay a sum of around $600m in payments throughout the programs which includes license and milestone payments and tiered royalties up to double digits on worldwide sales of products resulting from the alliance to Regulus.
However, Regulus has taken responsibility to identify compounds targeting four microRNAs through to completion of proof of concept trials.
The agreement allows GSK to license the worldwide development and commercialization rights under each target microRNA.